| Ashley Helen Malcolm, MD | |
|
705 Main St, Danville, VA 24541-1803 | |
| (434) 791-4122 | |
| (434) 791-4126 |
| Full Name | Ashley Helen Malcolm |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 705 Main St, Danville, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205030913 | NPI | - | NPPES |
| VV3910A | Other | VA | MEDICARE PART B |
| 15787696910 | Medicaid | VA | |
| 491863 | Other | VA | MEDICARE NGS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hshs St Elizabeth's Hospital | O fallon, IL | Hospital |
| St Josephs Hospital | Breese, IL | Hospital |
| St Joseph's Hospital | Highland, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America-illinois Hospitalists, Llp | 3274765904 | 62 |
News Archive
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
According to two new studies from the University of Birmingham and Tommy's National Centre for Miscarriage Research, women who have bleeding during early pregnancy and who have had earlier miscarriages could benefit from a course of progesterone, with about 8,500 babies being saved each year.
Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
Imagine if dentists could find clear signs of tooth decay long before dental lesions turn into cavities and without using X-rays. A new device cleared for commercialization this month by the Food and Drug Administration (FDA) is a potential tool for dentists to do just that.
› Verified 2 days ago
| Entity Name | Midwest Emergency Sparta, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194162370 PECOS PAC ID: 0345481255 Enrollment ID: O20130718000343 |
News Archive
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
According to two new studies from the University of Birmingham and Tommy's National Centre for Miscarriage Research, women who have bleeding during early pregnancy and who have had earlier miscarriages could benefit from a course of progesterone, with about 8,500 babies being saved each year.
Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
Imagine if dentists could find clear signs of tooth decay long before dental lesions turn into cavities and without using X-rays. A new device cleared for commercialization this month by the Food and Drug Administration (FDA) is a potential tool for dentists to do just that.
› Verified 2 days ago
| Entity Name | Cep America-illinois Hospitalists, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841613403 PECOS PAC ID: 3274765904 Enrollment ID: O20140411001788 |
News Archive
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
According to two new studies from the University of Birmingham and Tommy's National Centre for Miscarriage Research, women who have bleeding during early pregnancy and who have had earlier miscarriages could benefit from a course of progesterone, with about 8,500 babies being saved each year.
Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
Imagine if dentists could find clear signs of tooth decay long before dental lesions turn into cavities and without using X-rays. A new device cleared for commercialization this month by the Food and Drug Administration (FDA) is a potential tool for dentists to do just that.
› Verified 2 days ago
| Entity Name | Cep America - Illinois Snf Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073069415 PECOS PAC ID: 8022306737 Enrollment ID: O20161012002933 |
News Archive
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
According to two new studies from the University of Birmingham and Tommy's National Centre for Miscarriage Research, women who have bleeding during early pregnancy and who have had earlier miscarriages could benefit from a course of progesterone, with about 8,500 babies being saved each year.
Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
Imagine if dentists could find clear signs of tooth decay long before dental lesions turn into cavities and without using X-rays. A new device cleared for commercialization this month by the Food and Drug Administration (FDA) is a potential tool for dentists to do just that.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Helen Malcolm, MD 705 Main St, Danville, VA 24541-1803 Ph: (434) 791-4122 | Ashley Helen Malcolm, MD 705 Main St, Danville, VA 24541-1803 Ph: (434) 791-4122 |
News Archive
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
According to two new studies from the University of Birmingham and Tommy's National Centre for Miscarriage Research, women who have bleeding during early pregnancy and who have had earlier miscarriages could benefit from a course of progesterone, with about 8,500 babies being saved each year.
Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia occurring in multiple relatives in individual families. The discovery of the PAX5 gene mutation was led by St. Jude Children's Research Hospital and others. The work appears in the current advance online edition of the scientific journal Nature Genetics.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
Imagine if dentists could find clear signs of tooth decay long before dental lesions turn into cavities and without using X-rays. A new device cleared for commercialization this month by the Food and Drug Administration (FDA) is a potential tool for dentists to do just that.
› Verified 2 days ago
Dr. Kimaya Ryan Council, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 109 Bridge St Ste 201, Danville, VA 24541 Phone: 434-799-4488 Fax: 434-773-6977 | |
Dr. Thomas Edwin Wall, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 109 Bridge St Ste 201, Danville, VA 24541 Phone: 434-799-4488 Fax: 434-773-6977 | |
Katie Sue Woods, FNP-C Family Medicine Medicare: Medicare Enrolled Practice Location: 450 Piney Forest Rd, Danville, VA 24540 Phone: 434-799-1565 Fax: 434-792-1405 | |
Dr. Angeli A Niravel, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 142 S Main St, Danville, VA 24541 Phone: 434-799-3859 Fax: 434-773-6803 | |
Dr. Brandon Wayne Crawford, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 142 S Main St, Danville, VA 24541 Phone: 434-799-2100 | |
Dr. Bonnie Neal Burnham, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 S Main St, Suite 3200, Danville, VA 24541 Phone: 434-799-4488 | |
Andreshia Brooks, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 173 Executive Dr, Danville, VA 24541 Phone: 434-791-4110 |